AMGEN INCAMGN
AMGEN INC Financial Overview 2021–2025
Amgen defied the typical pharmaceutical "patent cliff" narrative in FY2025, delivering 10% sales growth driven by a 13% surge in volume rather than price increases. This performance validates a capital-intensive strategy to replace eroding legacy revenue with aggressive M&A and pipeline diversification. The company’s financial arc reflects this successful pivot, as total product sales climbed from $24.3 billion in FY2021 to $35.1 billion by the end of FY2025, effectively outpacing the decline of former blockbusters like Enbrel and Neulasta.
The transformation hinged on the $27.8 billion acquisition of Horizon Therapeutics and the scaling of next-generation therapies. While older drugs faced biosimilar headwinds, the cholesterol drug Repatha saw sales jump 36% to $3.0 billion, and the asthma treatment TEZSPIRE grew 52% in FY2025. To sustain this momentum, management increased R&D investment by 22% to $7.3 billion, focusing heavily on late-stage clinical trials. Despite the overhang of a major IRS tax dispute, the market valued this refreshed growth engine at 23.0x earnings with a market capitalization of $176.4 billion at the close of FY2025.
Recent Developments (Q3 and Q4 2025)
In Q3 2025, revenue expanded 12% to $9.6 billion, fueling a 14% rise in quarterly net income to $3.2 billion. This operational momentum extended into early 2026, highlighted by a 34% sales increase for the osteoporosis drug EVENITY and full FDA approval for IMDELLTRA. Strategic adjustments also included the January 2026 termination of a collaboration agreement with Kyowa Kirin to streamline the development portfolio.
Bullish investors emphasize the $8.4 billion in operating cash flow generated in the first nine months of 2025, which supported robust debt reduction and dividend payments. However, bears remain cautious regarding upcoming patent expirations for Prolia and XGEVA, which face accelerated biosimilar threats. Trading at 25.9x earnings with a market capitalization of $198.9 billion as of February 2026, the stock reflects elevated expectations for the newer oncology and inflammation pipeline to offset legacy declines.
What to watch: Commercial uptake of IMDELLTRA; acceleration of biosimilar erosion for bone health franchises.
Rev
$36.75B
FY2025
NI
$7.71B
FY2025
EPS
$14.33
FY2025
OCF
$9.96B
FY2025
Year-over-year comparison from 10-K annual reports
Data from SEC Company Facts
Recent SEC Filings
AMGEN INC 8-K Report, Financial Results (Feb 3, 2026)
Amgen Inc. (AMGN) has filed an 8-K report on February 3, 2026, announcing its unaudited financial results for the fourth quarter and full year ended December 31, 2025. The report primarily furnishes a press release detailing these results, which includes a significant focus on non-GAAP financial measures. These non-GAAP measures, such as non-GAAP earnings per share, operating income, and margins, are presented to provide investors with a more comprehensive understanding of the company's ongoing business performance and facilitate comparisons across periods. The company explicitly states its belief that these non-GAAP metrics, alongside Free Cash Flow (FCF) and a debt leverage ratio, offer valuable supplementary insights. Amgen utilizes these measures internally for budgeting, financial planning, and performance evaluation. Key adjustments to GAAP figures include the exclusion of acquisition-related expenses, restructuring and cost savings initiatives, and certain other items like investment gains/losses and legal proceeding costs. Investors should note that these non-GAAP measures are not a substitute for GAAP reporting but are intended to enhance analytical perspectives.
AMGEN INC 8-K Report, Agreement Terminated (Jan 30, 2026)
Amgen Inc. (AMGN) announced on January 30, 2026, the termination of its License and Collaboration Agreement with Kyowa Kirin Co., Ltd., originally dated June 1, 2021. This termination is set to become effective upon receiving the necessary regulatory approvals, signaling a potential shift in Amgen's strategic partnerships and pipeline development. While the specific reasons for termination and the financial implications are not detailed in this filing, investors should monitor future communications for updates on how this development might impact Amgen's ongoing research and development efforts, particularly concerning any products or technologies covered under the terminated agreement. The agreement with Kyowa Kirin, if significant, could have implications for revenue streams, cost-sharing, or market access for certain therapeutic areas.
AMGEN INC 8-K Report, Financial Results (Nov 4, 2025)
Amgen Inc. (AMGN) has filed a Form 8-K detailing its third quarter 2025 financial results, announced via a press release on November 4, 2025. The filing primarily furnishes the press release which includes the company's unaudited financial performance for the three and nine months ended September 30, 2025, as well as its financial position as of that date. Investors should note that Amgen is presenting both GAAP and non-GAAP financial measures, with a detailed reconciliation of these figures provided within the press release. The non-GAAP measures, including earnings per share, operating income, operating margin, tax rate, and operating expenses, are intended to offer a more insightful view of the company's ongoing operational performance by excluding certain items. These excluded items notably include acquisition-related expenses, costs associated with restructuring and cost-saving initiatives, and other non-ordinary course items such as investment gains/losses and legal proceeding costs. Amgen also highlights Free Cash Flow (FCF) as a key liquidity metric.
AMGEN INC 8-K Report, Financial Results (Aug 5, 2025)
Amgen Inc. (AMGN) has filed an 8-K report on August 5, 2025, furnishing its Second Quarter 2025 earnings press release. The release, dated August 5, 2025, details the company's unaudited financial results for the period ending June 30, 2025, and its financial position as of that date. Investors should note that Amgen, in its reporting, provides both GAAP and a range of non-GAAP financial measures, including non-GAAP earnings per share, operating income, operating margin, tax rate, and operating expenses. The company also reports Free Cash Flow (FCF). Amgen utilizes these non-GAAP measures to offer a more comprehensive view of its ongoing business operations and to facilitate comparisons across periods. Key adjustments from GAAP to non-GAAP figures include acquisition-related expenses (such as amortization and impairment of acquired intangible assets and inventory), costs associated with restructuring and cost savings initiatives, and other miscellaneous items like gains/losses on investments and legal proceeding impacts. These adjustments are made to present a clearer picture of operational performance and allow for better internal evaluation and external comparisons.
AMGEN INC 8-K Report, Shareholder Vote Results (May 27, 2025)
Amgen Inc. (AMGN) filed an 8-K report on May 27, 2025, detailing the outcomes of its annual meeting of stockholders held on May 22, 2025. The report primarily covers the election of directors, advisory votes on executive compensation, and the ratification of independent auditors. All 12 director nominees were overwhelmingly elected to serve a one-year term. Additionally, shareholders provided an advisory vote to approve executive compensation, which passed with a significant majority. Furthermore, the company's selection of Ernst & Young LLP as its independent registered public accountants for the fiscal year ending December 31, 2025, was ratified by stockholders. The voting results across all presented proposals indicate strong shareholder support for the company's governance and financial oversight practices. No other business was presented or voted upon during the meeting.
View all 8-K filings →